Nektar to Present Key Rezpegaldesleukin Data at EADV 2026

Event summary

Nektar will present three oral presentations on rezpegaldesleukin at EADV 2026, including 6-month off-treatment data from the REZOLVE-AA study.
The REZOLVE-AA study evaluated severe-to-very-severe alopecia areata patients, with primary endpoint measured by the Severity of Alopecia Tool (SALT).
REZOLVE-AD study data will also be presented, including maintenance data and multi-omic findings from a biomarker sub-study.
Nektar will host an investor call on October 1, 2026, to discuss the new data.

The big picture

Nektar's presentations at EADV 2026 come at a critical juncture for rezpegaldesleukin, as the company seeks to differentiate its lead candidate in the crowded autoimmune disease space. The focus on durability of response and multi-omic profiling aligns with broader industry trends toward precision medicine and long-term efficacy data. Success in these areas could position Nektar as a key player in addressing underlying immunological dysfunction in chronic inflammatory conditions.

What we're watching

Clinical Efficacy: How the 6-month off-treatment data from REZOLVE-AA will impact the perceived durability of rezpegaldesleukin's effects in alopecia areata.
Regulatory Pathway: Whether the new data will strengthen Nektar's position with the FDA, given the Fast Track designations for both atopic dermatitis and alopecia areata.
Market Differentiation: The pace at which Nektar can establish rezpegaldesleukin as a first-in-class regulatory T cell stimulator in a competitive autoimmune disease market.